Latest & greatest articles for ranitidine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ranitidine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ranitidine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ranitidine

1. Ranitidine

Ranitidine Top results for ranitidine - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ranitidine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Ranitidine

Ranitidine USE OF H2 RECEPTOR ANTAGONISTS IN PREGNANCY 0344 892 0909 USE OF H2 RECEPTOR ANTAGONISTS IN PREGNANCY (Date of issue: January 2015 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Histamine H2 (H 2 ) receptor antagonists (...) (cimetidine, famotidine, nizatidine and ranitidine) reduce gastric acid output and thus gastric acidity. H 2 receptor antagonists are used in the symptomatic relief of chronic episodic dyspepsia and gastro-oesophageal reflux disease, in the prevention and treatment of gastric or duodenal ulceration, and prior to general anaesthesia in patients at risk of acid aspiration. The BNF suggests ranitidine as the preferred H 2 receptor antagonist for use in pregnancy after lifestyle modification, and antacid

UK Teratology Information Service2014

3. Bolus or intravenous infusion of ranitidine: effects on gastric pH and acid secretion. A comparison of relative efficacy and cost.

Bolus or intravenous infusion of ranitidine: effects on gastric pH and acid secretion. A comparison of relative efficacy and cost. Bolus or intravenous infusion of ... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1990 ) Volume: 112 , Issue: 5 , Pages: 334-339 PubMed: Available from or Find this paper at: Abstract STUDY OBJECTIVE: To compare the effects of intravenous bolus injection (...) of ranitidine, continuous intravenous infusion of ranitidine, and placebo on gastric pH, acid secretion, and plasma ranitidine concentration during a 24-hour period, and to determine by survey the use, delivery methods, and costs of histamine H2-receptor antagonists in intensive care units. DESIGN: Double-blind, Latin-square randomized, prospective measurement of the gastric pH, acid output, and plasma ranitidine concentration over 24 hours in response to six treatment regimens in 12 patients with inactive

Annals of Internal Medicine2013

4. Cohort study: Ranitidine use is associated with increased morbidity and mortality in very low birthweight infants

Cohort study: Ranitidine use is associated with increased morbidity and mortality in very low birthweight infants Ranitidine use is associated with increased morbidity and mortality in very low birthweight infants | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ranitidine use is associated with increased morbidity and mortality in very low birthweight infants Article Text Aetiology Cohort study Ranitidine use is associated with increased morbidity and mortality in very low birthweight infants C Michael Cotten , William F Malcolm Statistics from

Evidence-Based Medicine (Requires free registration)2013

5. The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials

The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials Clark K, Lam LT, Gibson S, Currow D CRD summary The authors concluded that pre-medication of elective surgery patients (...) with ranitidine (histamine-2 blocker) was more effective than proton-pump inhibitors in reducing the volume of gastric secretions and reducing gastric acidity. The conclusions reflected the evidence presented, but should be interpreted with caution given the potential for publication bias, reviewer error and bias, and the limitations of small sample sizes. Authors' objectives To compare the effect of proton pump inhibitors with histamine-2 blockers on gastric secretions. Searching MEDLINE, EMBASE and CINHAL

DARE.2009

6. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole

Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole BACKGROUND: The use of non-steroidal anti-inflammatory drugs (NSAID) is associated with an increased risk of gastric ulcer (GU) development. METHODS: This multicentre, randomized, double-blind, parallel-group trial compared endoscopic healing rates at 4 and 8 weeks after treatment with oral esomeprazole 40 or 20 mg once daily, or ranitidine (...) 150 mg twice daily, in patients with 1 baseline GU > or = 5 mm but no GUs or duodenal ulcers >25 mm in diameter who received continued cyclooxygenase-2-selective or non-selective NSAID therapies. The primary outcome was the percentage of patients in each treatment group who had no GUs at week 8. RESULTS: Four hundred and forty patients were randomized to treatment. At week 8, GU healing rates (95% CI) with esomeprazole 40 mg, esomeprazole 20 mg and ranitidine were 85.7 (79.8-91.7)%, 84.8

EvidenceUpdates2007

7. Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use?

Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use? Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of serious gastroduodenal events. To minimise these risks, patients often require concomitant acid-suppressive therapy. We conducted a literature review of clinical trials examining use of ranitidine 150 mg twice daily to heal gastroduodenal ulcers (GU) in NSAID recipients. Seven studies were (...) identified. After 8 weeks' treatment with ranitidine, GU healing rates ranged from 50% to 74% and rates of duodenal ulcer (DU) healing ranged from 81% to 84%. Ranitidine was more effective when NSAIDs were discontinued (healing rates reaching 95% and 100%, respectively). The ulcer healing rate with sucralfate was similar to that of ranitidine. However, proton pump inhibitor (PPI) therapy was associated with significantly greater rates of both GU and DU healing than ranitidine; 8-week GU rates were 92

EvidenceUpdates2006 Full Text: Link to full Text with Trip Pro

8. Six-month management of patients following treatment for gastroesophageal reflux disease symptoms: a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical pra

Six-month management of patients following treatment for gastroesophageal reflux disease symptoms: a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical pra Six-month management of patients following treatment for gastroesophageal reflux disease symptoms: a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general (...) medical practitioners setting Six-month management of patients following treatment for gastroesophageal reflux disease symptoms: a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting Hansen A N, Wahlqvist P, Jorgensen E, Bergheim R, Fagertun H, Lund H, Moum B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each

NHS Economic Evaluation Database.2005

9. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study

A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study (...) Veldhuyzen van Zanten S J, Chiba N, Armstrong D, Barkun A, Thomson A, Smyth S, Escobedo S, Lee J, Sinclair P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared omeprazole (20 mg once daily), ranitidine (150 mg twice

NHS Economic Evaluation Database.2005

10. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing (...) and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Caro J J, Salas M, Ward A Authors' objectives To estimate the healing and relapse rates in the acute and maintenance treatment of gastroesophageal reflux disease (GERD) with the newer proton-pump inhibitors (PPIs) lansoprazole, rabeprazole and pantoprazole, compared

DARE.2001

11. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole

A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole A systematic comparison of triple therapies for treatment of Helicobacter pylori (...) infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole Janssen M J, Van Oijen A H, Verbeek A L, Jansen J B, De Boer W A Authors' objectives To evaluate whether there is a difference in the efficacy between triple therapies with proton-pump inhibitor (PPI) or ranitidine bismuth citrate (RBC) plus clarithromycin and either amoxicillin or a nitroimidazole, for the treatment of Helicobacter pylori (H. pylori) infection. Searching

DARE.2001

12. Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies

Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies van Oijen A H, Verbeek A L, Jansen J B, de Boer W A Authors' objectives (...) To compare treatment of Helicobacter pylori infection with ranitidine bismuth citrate- and proton pump inhibitor-based triple therapies. Searching The authors searched MEDLINE and Current Contents, and manually reviewed abstracts submitted to meetings of the American Gastroenterological Association (Digestive Disease and the United European Gastroenterology weeks) and the European Helicobacter Study Group, for the period 1996 to 1999. Study selection Study designs of evaluations included in the review

DARE.2000

13. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials

Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials Messori A, Trippoli (...) S, Vaiani M, Gorini M, Corrado A Authors' objectives To determine the effectiveness of ranitidine and sucralfate in the prevention of stress ulcer in critical patients, and to assess if these treatments affect the risk of nosocomial pneumonia. Searching The authors searched MEDLINE from 1966 to June 2000 using the keywords 'stress', 'pneumonia', 'ranitidine' and 'sucralfate'. Randomised studies were identified using the keywords 'randomized controlled trial' or 'random'. The search

DARE.2000

14. Helicobacter pylori eradication: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics for 1 week. A meta-analysis of efficacy

Helicobacter pylori eradication: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics for 1 week. A meta-analysis of efficacy Helicobacter pylori eradication: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics for 1 week. A meta-analysis of efficacy Helicobacter pylori eradication: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics for 1 week. A meta-analysis of efficacy Gisbert J P, Gonzalez L, Calvet X, Roque M (...) , Gabriel R, Pajares J M Authors' objectives To compare the efficacy of proton-pump inhibitors (PPI) versus ranitidine bismuth citrate (RBC) with two antibiotics for 1 week in Helicobacter pylori (H. pylori) eradication. Searching Searches were performed in the PubMed database up to October 1999. The search strategies are reported in the paper. A manual search of abstracts from 1995 to 1999 was also undertaken from the following congresses: International Workshop on Gastroduodenal Pathology

DARE.2000

15. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis

Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis Ofman J J, Yamashita B D, Siddique R M, Larson L R, Willian M K Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of rabeprazole (RAB), 20 mg/day for 8 weeks, and ranitidine (RAN), 150 mg 4 times daily for 8 weeks, as initial and maintenance therapy in patients with erosive oesophagitis. Type of intervention Treatment. Economic study type Cost-effectiveness

NHS Economic Evaluation Database.2000

16. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia

Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia Kaplan-Machlis B, Spiegler G E, Zodet (...) M W, Revicki D A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This study considered omeprazole sodium (20 mg once daily) and ranitidine hydrochloride (150 mg twice daily) for the treatment of symptomatic

NHS Economic Evaluation Database.2000

17. Management of acid-related dyspepsia in general practice: cost-effectiveness analysis comparing an omeprazole vs an antacid-alginate/ranitidine management strategy

Management of acid-related dyspepsia in general practice: cost-effectiveness analysis comparing an omeprazole vs an antacid-alginate/ranitidine management strategy Management of acid-related dyspepsia in general practice: cost-effectiveness analysis comparing an omeprazole vs an antacid-alginate/ranitidine management strategy Management of acid-related dyspepsia in general practice: cost-effectiveness analysis comparing an omeprazole vs an antacid-alginate/ranitidine management strategy Mason I (...) , Marchant N J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Management of acid-related dyspepsia in general practice using either omeprazole or antacid-alginate/ranitidine. Type of intervention Treatment. Economic study type Cost

NHS Economic Evaluation Database.1999

18. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease

Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease Stalhammar N, Carlsson J, Peacock R, Muller-Lissner S, Bigard M, Porro G B, Ponce J, Hosie J, Scott M, Weir D G, Fulton C, Gillon (...) K, Bardhan K D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of omeprazole (10 or 20 mg once daily) or ranitidine (150 mg twice daily) as initial therapy, and subsequent open maintenance treatment, following initial

NHS Economic Evaluation Database.1999

19. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials

Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1999

20. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group.

Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. 10024259 1999 03 24 1999 03 24 2014 06 17 0959-8138 318 7182 1999 Feb 20 BMJ (Clinical research ed.) BMJ Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. 502-7 To assess intermittent treatment over 12 months in patients (...) with symptomatic gastro-oesophageal reflux disease. Randomised, multicentre, double blind, controlled study. Patients with heartburn and normal endoscopy results or mild erosive changes received omeprazole 10 mg or 20 mg daily or ranitidine 150 mg twice daily for 2 weeks. Patients remaining symptomatic had omeprazole 10 mg or ranitidine dose doubled for another 2 weeks while omeprazole 20 mg was continued for 2 weeks. Patients who were symptomatic or mildly symptomatic were followed up for 12 months

BMJ1999 Full Text: Link to full Text with Trip Pro